Article
Oncology
Giovanna Barbero, Roberta Zuntini, Pamela Magini, Laura Desiderio, Michela Bonaguro, Anna Myriam Perrone, Daniela Rubino, Mina Grippa, Antonio De Leo, Claudio Ceccarelli, Lea Godino, Sara Miccoli, Simona Ferrari, Donatella Santini, Pierandrea De Iaco, Claudio Zamagni, Giovanni Innella, Daniela Turchetti
Summary: Ovarian cancer is a highly lethal malignancy and genetic defects, including BRCA1 and BRCA2 alterations, are common in patients. A comprehensive study of 30 ovarian cancer patients revealed that 23% had BRCA alterations detectable by clinical testing, while 17% showed epigenetic silencing of BRCA1 in the tumor. Patients with BRCA deficit had greater genomic instability but better survival compared to those without BRCA deficit.
Article
Oncology
Hyeong In Ha, Eun Young Park, Kyung Jin Eoh, Yeon Jee Lee, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim
Summary: This study investigated the clinical significance of the ovarian cancer cluster region (OCCR) in BRCA1 and BRCA2 genes. The results showed that patients with BRCA1 pathogenic variants (PVs) in the OCCR region had shorter progression-free survival (PFS) compared to those outside the OCCR. This trend was more pronounced in the platinum-sensitive subgroup. However, no significant differences were found in overall survival (OS) between patients with BRCA1/2 PVs, regardless of the variant location.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Kate Gersekowski, Rachel Delahunty, Kathryn Alsopb, Ellen L. Goode, Julie M. Cunningham, Stacey J. Winham, Paul Pharoah, Honglin Song, Susan Jordan, Sian Fereday, Anna DeFazio, Michael Friedlander, Andreas Obermair, Penelope M. Webb
Summary: The adverse effect of smoking on survival may be stronger for women with a BRCA variant, while the associations between physical activity, BMI, and alcohol intake and survival are unclear.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Pavlina Spiliopoulou, Samantha Hinsley, Iain A. McNeish, Patricia Roxburgh, Ros Glasspool
Summary: Oral metronomic cyclophosphamide showed clinical benefit in approximately 48% of patients with recurrent ovarian cancer. The presence of a gBRCA1/2 mutation may serve as an independent predictor of response to treatment.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)
Article
Oncology
Yomali Ferreyra, Gina Rosas, Alicia M. Cock-Rada, Jhajaira Araujo, Leny Bravo, Franco Doimi, Jhoysi Casas, Maria de los Angeles Clavo, Joseph A. Pinto, Carolina Belmar-Lopez
Summary: This retrospective study describes the prevalence of pathogenic/likely pathogenic (P/LP) variants and variants of uncertain/unknown significance (VUS) in BRCA1 and BRCA2 genes in Peruvian breast and ovarian cancer patients. The study found that 14.7% of breast cancer patients and 20.7% of ovarian cancer patients carried P/LP variants in BRCA1/2. The most frequent pathogenic variants were c.2105dupT in BRCA1 and c.8023A>G in BRCA2.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Diana Goncalves, Ana Salome Pires, Ines A. Marques, Ines Gomes, Gabriela Sousa, Maria Filomena Botelho, Ana Margarida Abrantes
Summary: Individuals with hereditary breast and ovarian cancer (HBOC) syndrome have a higher risk of developing cancer compared to the general population, but studies on the association between exposure to ionizing radiation and cancer risk have inconsistent results.
Article
Oncology
Robert D. D. Morgan, George J. J. Burghel, Nicola Flaum, Michael Bulman, Philip Smith, Andrew R. R. Clamp, Jurjees Hasan, Claire L. L. Mitchell, Zena Salih, Emma R. R. Woodward, Fiona Lalloo, Emma J. J. Crosbie, Richard J. J. Edmondson, Helene Schlecht, Gordon C. C. Jayson, D. Gareth R. Evans
Summary: Approximately 15% of patients diagnosed with high-grade non-mucinous epithelial ovarian cancer (EOC) have a germline BRCA1/2 mutation, with somatic mutations occurring more frequently in patients aged >= 80. Germline BRCA1/2 testing in this age group can be reserved for those with a detectable tumour BRCA1/2 mutation. Testing for tumour BRCA1/2 and homologous recombination deficiency is sufficient for patients aged >= 80 with non-mucinous high-grade EOC.
Article
Oncology
Naela Agha, Bader Alshamsan, Sharifa Al-Farsi, Heba Aly Ateya, Fahad A. Almugbel, Hazem Abdullah Alotaibi, Ayman Omar, Amgad Shahin Mohamed, Hanan Alharthy, Tusneem Elhassan, Hany Salem, Hamed Alhusaini
Summary: This study aims to determine the frequency, pattern, and impact of BRCA gene mutations on patient characteristics and outcomes in Saudi women with ovarian cancer (OC). The study found a higher prevalence of BRCA mutations in Saudi women with OC compared to regional and international figures and observed better clinical outcomes in women with BRCA mutations.
Article
Biochemistry & Molecular Biology
Kristie-Ann Dickson, Tao Xie, Christian Evenhuis, Yue Ma, Deborah J. Marsh
Summary: PARP inhibitors have shown efficacy in treating tumors with BRCA gene defects, improving survival outcomes. Variability exists between different PARP inhibitors in terms of chemical structure, toxicity, and cell survival, with acquired resistance being a concerning issue that needs further exploration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Lieke Lanjouw, Marian J. E. Mourits, Joost Bart, Arja ter Elst, Lieke P. Berger, Annemieke H. van der Hout, Naufil Alam, Geertruida H. de Bock
Summary: This study aimed to evaluate the BRCA1/2 testing rates in patients with epithelial ovarian cancer and compare the rates between germline testing and tumor-first testing. The results showed suboptimal testing rates and indicated that patients with non-high-grade serous carcinoma were less likely to receive BRCA1/2 testing. This suggests that clinicians may not be adhering to the guidelines recommending testing for all patients with epithelial ovarian cancer.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Medicine, Research & Experimental
Dorra Ben Ayed-Guerfali, Wala Ben Kridis-Rejab, Nihel Ammous-Boukhris, Wajdi Ayadi, Slim Charfi, Afef Khanfir, Tahia Sellami-Boudawara, Mounir Frikha, Jamel Daoud, Raja Mokdad-Gargouri
Summary: The study revealed a 14.17% frequency of BRCA germline mutations in Tunisian patients with high risk of breast/ovarian cancer, with some recurrent mutations found in a significant proportion of familial cases of breast and ovarian cancer.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Chen Nahshon, Yakir Segev, Meirav Schmidt, Ofer Lavie
Summary: This study examines the attitudes of BRCA1/2 mutation carriers towards surgical risk reduction procedures. The results show high performance rates for risk reduction bilateral salpingo-oophorectomy, though hysterectomy was added in only 10% of cases. Additionally, only 33% of patients opted for risk reduction mastectomy, despite high awareness and acceptance rates. These findings provide important insights for clinicians counseling BRCA1/2 mutation carriers and highlight the need for personalized management plans.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Alicja Lukomska, Janusz Menkiszak, Jacek Gronwald, Joanna Tomiczek-Szwiec, Marek Szwiec, Marek Jasiowka, Pawel Blecharz, Tomasz Kluz, Malgorzata Stawicka-Nielacna, Radoslaw Madry, Katarzyna Bialkowska, Karolina Prajzendanc, Wojciech Kluzniak, Cezary Cybulski, Tadeusz Debniak, Tomasz Huzarski, Aleksandra Toloczko-Grabarek, Tomasz Byrski, Piotr Baszuk, Steven A. Narod, Jan Lubinski, Anna Jakubowska
Summary: In Poland, ovarian cancer is the fourth leading cause of cancer-related deaths among women. Founder mutations in BRCA1, BRCA2, PALB2, RAD51C, and CHEK2 genes are associated with breast and ovarian cancer. This study aimed to analyze the frequency and magnitude of 21 recurrent founder germline mutations in these genes with ovarian cancer risk in Poland, recommending testing for a panel of 18 mutations in affected individuals and their first-degree female relatives.
Article
Genetics & Heredity
Marion Imbert-Bouteille, Carole Corsini, Marie-Christine Picot, Lucas Mizrahy, Sandrine Akouete, Helena Huguet, Frederic Thomas, David Genevieve, Patrice Taourel, Marc Ychou, Virginie Galibert, Chloe Rideau, Karen Baudry, Tatiana Kogut Kubiak, Isabelle Coupier, Remy Hobeika, Yvette Macary, Alain Toledano, Jerome Solassol, Antoine Maalouf, Jean-Pierre Daures, Pascal Pujol
Summary: The occurrence of very early-onset breast cancer (VEO-BC) or ovarian cancer (VEO-OC) in families with BRCA1 or BRCA2 mutation (BRCAm) does not significantly affect the age at which relatives develop breast or ovarian cancer. While some families may have early-onset cancer cases, the probability of early-onset cancer is not increased in families with VEO-BC or VEO-OC.
Article
Genetics & Heredity
Trong-Nhan N. Le, Van-Khanh Tran, Thu-Thuy Nguyen, Nam S. Vo, Tham H. Hoang, Hoang-Long Vo, Thanh-Hai T. Nguyen, Phuoc-Dung Nguyen, Viet-Tien Nguyen, Thanh-Van Ta, Huy-Thinh Tran
Summary: This study screened for BRCA1 and BRCA2 gene mutations in Vietnamese breast and ovarian cancer patients, identifying multiple mutations and establishing a risk score associated with carrier status and family history. The findings have implications for planning screening programs and genetic testing in this population.
Article
Genetics & Heredity
Belinda Rahman, Anne Lanceley, Rebecca S. Kristeleit, Jonathan A. Ledermann, Michelle Lockley, Mary McCormack, Tim Mould, Lucy Side
JOURNAL OF MEDICAL GENETICS
(2019)
Article
Public, Environmental & Occupational Health
Chloe Shaw, Vasiliki Chrysikou, Anne Lanceley, Chris Lo, Sarah Hales, Gary Rodin
PATIENT EDUCATION AND COUNSELING
(2019)
Article
Oncology
Dimitrios A. Koutoukidis, Rebecca J. Beeken, Ranjit Manchanda, Matthew Burnell, Nida Ziauddeen, Moscho Michalopoulou, M. Tish Knobf, Anne Lanceley
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2019)
Meeting Abstract
Oncology
Felicia Roncolato, Rachel O'Connell, Florence Joly, Anne Lanceley, Felix Hilpert, Aikou Okamoto, Eriko Aotani, Sandro Pignata, Paul P. Donnellan, Amit M. Oza, Elisabeth Avall-Lundqvist, Jonathan S. Berek, Jalid Sehouli, Jonathan A. Ledermann, Dominique Berton-Rigaud, Belinda Emma Kiely, Michael Friedlander, Martin R. Stockler
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Oncology
Derek Kyte, Ameeta Retzer, Khaled Ahmed, Thomas Keeley, Jo Armes, Julia M. Brown, Lynn Calman, Anna Gavin, Adam W. Glaser, Diana M. Greenfield, Anne Lanceley, Rachel M. Taylor, Galina Velikova, Michael Brundage, Fabio Efficace, Rebecca Mercieca-Bebber, Madeleine T. King, Grace Turner, Melanie Calvert
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2019)
Article
Obstetrics & Gynecology
Jacqueline A. Nicholls, Anna L. David, Joseph Iskaros, Dimitrios Siassakos, Anne Lanceley
Summary: This study found that ante-natal consultations for interventions focus heavily on clinical framing and risk, while exploring the woman-centered narrative less effectively. Healthcare professionals need to pay more attention to the preferences and values of pregnant women during consent consultations to meet the requirements of UK law.
BMC PREGNANCY AND CHILDBIRTH
(2021)
Article
Obstetrics & Gynecology
Sophie Kennedy, Anne Lanceley, Melissa Whitten, Clodagh Kelly, Jacqueline Nicholls
Summary: Healthcare professionals in the labour ward tend to view consent as an agreement process rather than an exercise of choice, and often lack knowledge of the implications of current law. Communicating risks with women in an appropriate way at an appropriate time poses challenges, threatening the lawfulness of consent. Specialist training is recommended to assist professionals in providing timely consultation dialogues that respect women's right to choose.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
(2021)
Article
Oncology
Yeh Chen Lee, Madeleine T. King, Rachel L. O'Connell, Anne Lanceley, Florence Joly, Felix Hilpert, Alison Davis, Felicia T. Roncolato, Aikou Okamoto, Jane Bryce, Paul Donnellan, Amit M. Oza, Elisabeth Avall-Lundqvist, Jonathan S. Berek, Jonathan A. Ledermann, Dominique Berton, Jalid Sehouli, Amanda Feeney, Marie-Christine Kaminsky, Katrina Diamante, Martin R. Stockler, Michael L. Friedlander
Summary: The study aimed to evaluate the effects of chemotherapy on symptoms and health-related quality of life in women with platinum resistant/refractory recurrent ovarian cancer and those with chemotherapy 3 lines or more. The results showed that over 50% of the participants reported abdominal and psychological symptoms, with 40% experiencing improvements within 2 months of starting chemotherapy.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Anthropology
Ignacia Arteaga, Sahra Gibbon, Anne Lanceley
MEDICAL ANTHROPOLOGY
(2022)
Article
Psychology, Social
Soumitra Shankar Datta, Lindsay Fraser, Matthew Burnell, Shazia Nasreen, Manisha Ghosh, Aparupa Ojha, Tania Saha, Asima Mukhopadhyay, Anne Lanceley, Usha Menon
Summary: This study aimed to explore the association between adult attachment patterns and delays in accessing specialist oncology care in patients with ovarian cancer (OC). The results showed that higher attachment anxiety scores and being part of a multigenerational extended household were independently associated with delay in presentation to a cancer specialist. This finding highlights the importance of enhancing awareness and interaction with patients with insecure attachment styles in primary care.
JOURNAL OF PSYCHOSOCIAL ONCOLOGY
(2022)
Article
Obstetrics & Gynecology
Jacqueline Nicholls, Anna L. David, Joseph Iskaros, Anne Lanceley
Summary: This study investigated healthcare professionals' views and experiences of the consent process in antenatal and intrapartum care. The results indicate that there is a mismatch between what is required and what can be achieved in practice, highlighting the need for more support for healthcare professionals.
BMC PREGNANCY AND CHILDBIRTH
(2022)
Article
Oncology
Pratyusha Saha, Jameela Sheikh, Meghnaa Hebbar, Sudha Sundar, Anne Lanceley
Summary: The study explores the concerns of gynaecological cancer patients during COVID-19, highlighting their anxieties over treatment changes and the positive role of cancer charities in providing support through digital and conventional means. Real-time analysis of charity communications can help identify patient concerns and facilitate proactive support from healthcare providers.
EUROPEAN JOURNAL OF CANCER CARE
(2022)
Review
Psychology, Clinical
Sarah Davis, Marc Serfaty, Joe Low, Megan Armstrong, Nuriye Kupeli, Anne Lanceley
Summary: This study provides an overview of psychological distress in advanced cancer patients. The results suggest that experiential avoidance (EA) may be beneficial in the short term to alleviate distress but can impair function and limit engagement in life in the longer term. The study highlights the importance of understanding the complexity of EA behaviors and defining EA precisely for clinicians and researchers.
INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE
(2023)
Article
Oncology
Merel van Klinken, Emma Hafkamp, Anne Gualtherie van Weezel, Sarah Hales, Anne Lanceley, Gary Rodin, Christian Schulz-Quach, Froukje de Vries
Summary: This study assessed the feasibility and acceptability of CALM-N for oncology nurses and its impact on professional wellbeing. The results showed that CALM-N is a feasible and acceptable intervention for oncology nurses, with the potential to improve nurse-patient communication and the nurses' reflective capacities.
SEMINARS IN ONCOLOGY NURSING
(2023)
Article
Psychology, Clinical
Chloe Shaw, Chris Lo, Anne Lanceley, Sarah Hales, Gary Rodin
JOURNAL OF CONTEMPORARY PSYCHOTHERAPY
(2020)